{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:04:54Z","timestamp":1789477494330,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG30320 and IG33759"],"award-info":[{"award-number":["IG30320 and IG33759"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR M4C2I1.3 heal Italia project PE00000019 CUP B43D22000710006"],"award-info":[{"award-number":["PNRR M4C2I1.3 heal Italia project PE00000019 CUP B43D22000710006"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00828-7","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:07:52Z","timestamp":1789474072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer"],"prefix":"10.1186","volume":"15","author":[{"given":"M.","family":"Chiappa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Grasselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Canesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Marabese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dibitetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fruscio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Damia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"828_CR1","doi-asserted-by":"publisher","first-page":"102255","DOI":"10.1016\/j.ctrv.2021.102255","volume":"99","author":"H Vanacker","year":"2021","unstructured":"Vanacker H, Harter P, Labidi-Galy SI, Banerjee S, Oaknin A, Lorusso D, et al. PARP-inhibitors in epithelial ovarian cancer: actual positioning and future expectations. Cancer Treat Rev. 2021;99:102255. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102255.","journal-title":"Cancer Treat Rev"},{"key":"828_CR2","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3390\/cancers14071807","volume":"14","author":"M Chiappa","year":"2022","unstructured":"Chiappa M, Guffanti F, Anselmi M, Lupi M, Panini N, Wiesm\u00fcller L, et al. Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells. Cancers. 2022;14:1807. https:\/\/doi.org\/10.3390\/cancers14071807.","journal-title":"Cancers"},{"key":"828_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s10238-025-01776-y","volume":"25","author":"H Xiao","year":"2025","unstructured":"Xiao H, Han Z, Tang Y, Gao X, Xu M, Qiu S, et al. SLFN11, far from being limited to responding to cancer DNA damage. Clin Exp Med. 2025;25:304. https:\/\/doi.org\/10.1007\/s10238-025-01776-y.","journal-title":"Clin Exp Med"},{"key":"828_CR4","first-page":"371","volume":"2","author":"SJ Miknyoczki","year":"2003","unstructured":"Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, et al. Chemopotentiation of Temozolomide, Irinotecan, and Cisplatin Activity by CEP-6800, a Poly(ADP-Ribose) Polymerase Inhibitor. Mol Cancer Ther. 2003;2:371\u201382.","journal-title":"Mol Cancer Ther"},{"key":"828_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1748-717X-7-62","volume":"7","author":"K Miura","year":"2012","unstructured":"Miura K, Sakata K, Someya M, Matsumoto Y, Matsumoto H, Takahashi A, et al. The combination of olaparib and camptothecin for effective radiosensitization. Radiat Oncol. 2012;7:62. https:\/\/doi.org\/10.1186\/1748-717X-7-62.","journal-title":"Radiat Oncol"},{"key":"828_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/bjc.2014.378","volume":"111","author":"P Znojek","year":"2014","unstructured":"Znojek P, Willmore E, Curtin NJ. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. Br J Cancer. 2014;111:1319\u201326. https:\/\/doi.org\/10.1038\/bjc.2014.378.","journal-title":"Br J Cancer"},{"key":"828_CR7","doi-asserted-by":"publisher","first-page":"116663","DOI":"10.1016\/j.biopha.2024.116663","volume":"175","author":"KS Prabhu","year":"2024","unstructured":"Prabhu KS, Kuttikrishnan S, Ahmad N, Habeeba U, Mariyam Z, Suleman M, et al. H2AX: A key player in DNA damage response and a promising target for cancer therapy. Biomed Pharmacother. 2024;175:116663. https:\/\/doi.org\/10.1016\/j.biopha.2024.116663.","journal-title":"Biomed Pharmacother"},{"key":"828_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s42003-025-08444-7","volume":"8","author":"G Qi","year":"2025","unstructured":"Qi G, Ma H, Chen J, Gai P, Teng K. TTK activates ATR through RPA2 phosphorylation to promote olaparib resistance in ovarian cancer. Commun Biol Nat Publishing Group. 2025;8:1011. https:\/\/doi.org\/10.1038\/s42003-025-08444-7.","journal-title":"Commun Biol Nat Publishing Group"},{"key":"828_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41419-024-06894-1","volume":"15","author":"M Chiappa","year":"2024","unstructured":"Chiappa M, Decio A, Guarrera L, Mengoli I, Karki A, Yemane D, et al. Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas. Cell Death Dis. 2024;15:521. https:\/\/doi.org\/10.1038\/s41419-024-06894-1.","journal-title":"Cell Death Dis"},{"key":"828_CR10","unstructured":"Hycamtin | European Medicines Agency (EMA) [Internet]. 2018 [cited 2026 Apr 27]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hycamtin. Accessed 27 Apr 2026."},{"key":"828_CR11","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1158\/1078-0432.CCR-15-0652","volume":"22","author":"PM LoRusso","year":"2016","unstructured":"LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, et al. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016;22:3227\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0652.","journal-title":"Clin Cancer Res"},{"key":"828_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","volume":"6","author":"Y Pommier","year":"2006","unstructured":"Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6:789\u2013802. https:\/\/doi.org\/10.1038\/nrc1977.","journal-title":"Nat Rev Cancer"},{"key":"828_CR13","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1093\/nar\/gku088","volume":"42","author":"BB Das","year":"2014","unstructured":"Das BB, Huang SN, Murai J, Rehman I, Am\u00e9 J-C, Sengupta S, et al. PARP1\u2013TDP1 coupling for the repair of topoisomerase I\u2013induced DNA damage. Nucleic Acids Res. 2014;42:4435\u201349. https:\/\/doi.org\/10.1093\/nar\/gku088.","journal-title":"Nucleic Acids Res"},{"key":"828_CR14","unstructured":"EACR26-0679 [Internet]. [cited 2026 Aug 6]. https:\/\/storage.unitedwebnetwork.com\/files\/991\/abstract\/2026\/EACR26-0679.htm. Accessed 6 Aug 2026."},{"key":"828_CR15","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","volume":"28","author":"G Illuzzi","year":"2022","unstructured":"Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, et al. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022;28:4724\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0301.","journal-title":"Clin Cancer Res"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00828-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00828-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00828-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:07:54Z","timestamp":1789474074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00828-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["828"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00828-7","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The in vivo studies performed on PDXs were approved by the Italian Ministry of Health (approval number no 131\/2023-PR).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"94"}}